• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Invizyne Technologies Inc.

    11/18/24 7:58:02 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IZTC alert in real time by email
    SC 13D 1 formsc13d.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(a)

     

    Invizyne Technologies Inc.
    (Name of Issuer)

     

    Common Stock
    (Title of Class of Securities)

     

    461874109

    (CUSIP Number)

     

    Andrew D. Hudders, Esq.

    Golenbock Eiseman Assor Bell & Peskoe LLP,

    711 Third Avenue, Fl. 17, New York, New York 10017

    (212-907-7300)
    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    November 14, 2024
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    Page 2 of 5

     

    CUSIP NO.: 461874109

     

    1) NAME OF REPORTING PERSON  
      Paul Opgenorth  
    2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3) SEC Use Only  
    4) SOURCE OF FUNDS OO, PF
    5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ☐
    6) CITIZENSHIP OR PLACE OF ORGANIZATION United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7)

    SOLE VOTING POWER

     

    744,333
    8)

    SHARED VOTING POWER

     

    0
    9)

    SOLE DISPOSITIVE POWER

     

    744,333
    10)

    SHARED DISPOSITIVE POWER

     

    0

    11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 744,333
    12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
    13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.81%
    14) TYPE OF REPORTING PERSON IN

     

     
    Page 3 of 5

     

    ITEM 1.

    SECURITY AND ISSUER.

     

    The class of equity securities to which this Statement of Schedule 13D (this “Schedule 13D”) relates is shares of common stock, $0.000001 par value (the “Common Stock”) of Invizyne Technologies Inc., a Nevada corporation (the “Issuer”). The principal executive office of the Issuer is 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016.

     

    ITEM 2.IDENTITY AND BACKGROUND.

     

    (a) This Schedule 13D is being filed by Paul Opgenorth (the “Reporting Person”).

     

    (b) The Reporting Person’s principal business address is c/o 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016.

     

    (c) The Reporting Person is a Vice President, Development of the Issuer.

     

    (d) During the past five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) During the past five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or as a result of such a proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) The Reporting Person is a citizen of the United States of America.

     

    ITEM 3.SOURCE AND AMOUNT OF FUNDS AND OTHER CONSIDERATION.

     

    The securities were acquired by the Reporting Person in exchange for the interests in the predecessor entity and personal efforts in the development of the Issuer and the investment of $15,000.

     

    ITEM 4.PURPOSE OF TRANSACTION.

     

    The securities were initially acquired for investment purposes. The Reporting Person intends to review its investment in the Issuer on a continuing basis and will routinely monitor a wide variety of investment considerations, including, without limitation, current and anticipated future trading prices for the Common Stock, the Issuer’s financial position, operations, assets, prospects, strategic direction and business and other developments affecting the Issuer. The Reporting Person may from time to time take such actions with respect to its investment in the Issuer as it deems appropriate, including, without limitation, (i) acquiring additional shares or disposing of some or all of its shares of Common Stock (or other securities of the Issuer); (ii) changing its current intentions with respect to any or all matters referred to in this Item 4; and/or (iii) engaging in hedging, derivative or similar transactions with respect to any securities of the Issuer. Any acquisition or disposition of the Issuer’s securities may be made by means of open-market purchases or dispositions, privately negotiated transactions, direct acquisitions from or dispositions to the Issuer.

     

     
    Page 4 of 5

     

    At the date of this Schedule 13D, except as set forth in this Schedule 13D, the Reporting Person does not have any plans or proposals which would result in:

     

    (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

     

    (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

     

    (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

     

    (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or fill any existing vacancies on the board;

     

    (e) Any material change in the present capitalization or dividend policy of the Issuer;

     

    (f) Any other material change in the Issuer’s business or corporate structure;

     

    (g) Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

     

    (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

    (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1940; or

     

    (j) Any action similar to any of those actions enumerated above.

     

    ITEM 5.INTERESTS IN SECURITIES OF THE ISSUER.

     

    (a) As of November 18, 2024, the Reporting Person beneficially owned 744,333 shares of the Issuer’s Common Stock, representing approximately 7.81% of the shares of the Issuer’s Common Stock issued and outstanding as of such date. Excludes 9,739 shares of Common Stock subject to options that will vest in the future. The percentage is based on 9,528,797 shares issued and outstanding of the Issuer.

     

    (b) The Reporting Person has the sole power to vote and to dispose of 744,333 shares of Common Stock.

     

    (c) Not applicable.

     

    (d) Not applicable.

     

    (e) Not applicable.

     

    ITEM 6.CONTRACTS, ARRANGEMENTS UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

     

    None.

     

    ITEM 7.MATERIAL TO BE FILED AS EXHIBITS.

     

    None.

     

     
    Page 5 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated as of: November 18, 2024 /s/ Paul Opgenorth
      Paul Opgenorth

     

     

     

    Get the next $IZTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IZTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IZTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Heltzen Michael bought $20,345 worth of shares (1,888 units at $10.78), increasing direct ownership by 95% to 3,872 units (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    1/21/25 6:02:17 AM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Heltzen Michael bought $22,022 worth of shares (1,984 units at $11.10) (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    11/19/24 6:45:00 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IZTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Heltzen Michael bought $20,345 worth of shares (1,888 units at $10.78), increasing direct ownership by 95% to 3,872 units (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    1/21/25 6:02:17 AM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Heltzen Michael bought $22,022 worth of shares (1,984 units at $11.10) (SEC Form 4)

    4 - Invizyne Technologies Inc (0002010788) (Issuer)

    11/19/24 6:45:00 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bell Lon E

    3 - Invizyne Technologies Inc (0002010788) (Issuer)

    11/19/24 2:37:27 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IZTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes

    Rebranding Invizyne Technologies, Inc to eXoZymes Inc.Changing NASDAQ ticker from IZTC to EXOZIntroducing but not trademarking "exozymes" as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of "EXOZ" effective before the market open. No action is required by existing shareholders with respect to the name and ticker symbol c

    2/12/25 8:50:00 AM ET
    $IZTC
    $MDBH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

    Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and an application for a new ticker symbol. The company expects trading under the new ticker symbol of "EXOZ" to begin on February 12, 2025, subject to final approvals. In connection with the corporate name change, Company branding, including the corporate website, will be updated accordingly. No action is required by existing shareholders with respect to the name and

    2/10/25 11:00:00 AM ET
    $IZTC
    $MDBH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities

    Monrovia, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced it was awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF). The project is a cost share grant from the U.S. Department of Defense's BioMADE initiative, in partnership with the University of Georgia. It is one of 17 BioMADE projects announced on October 30, 2024, to drive the scale-up and commercialization of American biomanufactured products. "The nex

    11/19/24 9:05:00 AM ET
    $IZTC
    $MDBH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    $IZTC
    SEC Filings

    View All

    Invizyne Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - EXOZYMES INC. (0002010788) (Filer)

    2/11/25 5:27:46 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invizyne Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Invizyne Technologies Inc (0002010788) (Filer)

    11/18/24 4:45:36 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IZTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Invizyne Technologies Inc.

    SC 13D - Invizyne Technologies Inc (0002010788) (Subject)

    11/18/24 7:58:02 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Invizyne Technologies Inc.

    SC 13D - Invizyne Technologies Inc (0002010788) (Subject)

    11/18/24 7:58:02 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Invizyne Technologies Inc.

    SC 13D - Invizyne Technologies Inc (0002010788) (Subject)

    11/18/24 7:58:02 PM ET
    $IZTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care